Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Blr-Bio LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, WARD, AARON DUREL, who is the busiest examiner with 1 busiest examiner pending action. The prosecution is localized within 1 distinct art unit, reflecting a specific focus within the biotech sector. This lack of diversity in examiners and art units means the company's strategy is highly dependent on a single individual's interpretation.
The 1 pending office action is the only current point of engagement with the USPTO for this company. Since there is only 1 distinct examiner, the prosecution outcome for the Biotechnology & Pharmaceuticals portfolio is entirely dependent on the review of WARD, AARON DUREL. The use of 1 distinct art unit suggests that the technology is not being split across different examination divisions, which may simplify the management of the action. Practitioners must focus their resources on this single interaction to resolve the current workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18466680 | NOVEL DIAGNOSTIC AND METHOD OF SCREENING THERAPEUTICS FOR FIBROTIC CONDITIONS | WARD, AARON DUREL | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18466680 | NOVEL DIAGNOSTIC AND METHOD OF SCREENING THERAPEUTICS FOR FIBROTIC CONDITIONS | WARD, AARON DUREL | 1636 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBlr-Bio LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aaron Durel Ward has the most, with 1 of Blr-Bio LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
